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Abstract
Treatment of stroke with bone marrow stromal cells (BMSC) significantly enhances brain
remodeling and improves neurological function in non-diabetic stroke rats. Diabetes is a
major risk factor for stroke and induces neurovascular changes which may impact stroke
therapy. Thus, it is necessary to test our hypothesis that the treatment of stroke with BMSC
has therapeutic efficacy in the most common form of diabetes, type 2 diabetes mellitus
(T2DM). T2DM was induced in adult male Wistar rats by administration of a high fat diet in
combination with a single intraperitoneal injection (35mg/kg) of streptozotocin. These rats
were then subjected to 2h of middle cerebral artery occlusion (MCAo). T2DM rats received
BMSC (5x106, n = 8) or an equal volume of phosphate-buffered saline (PBS) (n = 8) via tail-
vein injection at 3 days after MCAo. MRI was performed one day and then weekly for 5
weeks post MCAo for all rats. Compared with vehicle treated control T2DM rats, BMSC
treatment of stroke in T2DM rats significantly (p<0.05) decreased blood-brain barrier disrup-
tion starting at 1 week post stroke measured using contrast enhanced T1-weighted imaging
with gadopentetate, and reduced cerebral hemorrhagic spots starting at 3 weeks post
stroke measured using susceptibility weighted imaging, although BMSC treatment did not
reduce the ischemic lesion volumes as demarcated by T2 maps. These MRI measurements
were consistent with histological data. Thus, BMSC treatment of stroke in T2DM rats initi-
ated at 3 days after stroke significantly reduced ischemic vascular damage, although BMSC
treatment did not change infarction volume in T2DM rats, measured by MRI.
Introduction
In the clinic, the vast majority (90–95%) of diabetic patients have type 2 diabetes mellitus
(T2DM) [1]. Diabetes with concomitant hyperglycemia is a chronic vascular disease [1].
Hyperglycemia induces a variety of biochemical changes within endothelial cells, including
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those in the cerebral vasculature [2], which instigates a cascade of events leading to vascular
endothelial cell dysfunction, and increased vascular permeability in various vascular beds in
humans and animal models [3]. Multiple cell and molecular pathways are involved in the dia-
betes-related changes in the blood-brain barrier (BBB) [4].
Diabetes increases risk of ischemic stroke, stroke recurrence and long-term mortality from
stroke, and worsens the overall neurological outcomes after stroke [5, 6]. Abnormalities in glu-
cose metabolism and vascular hemodynamics may play important roles in the pathogenic
progress of stroke in diabetic patients [5]. BBB damage and exacerbated secondary hemor-
rhagic transformation (HT) are consistent consequences of ischemic stroke in diabetic murine
animals [7–9]. BBB disruption persists much longer time after stroke in T2DM rats than in
non diabetic rats [9].
In non-diabetic rats, treatment of stroke with bone marrow stromal cells (BMSC) signifi-
cantly reduces vascular permeability in the ischemic brain and improves neurological function
within two weeks after stroke, compared with vehicle-treated non-diabetic stroke rats [10]. Sur-
prisingly, BMSC therapy administered at 24h after stroke in rats with type 1 diabetes mellitus
(T1DM) fails to improve neurological function, adversely increases BBB leakage and intracra-
nial hemorrhage two weeks after stroke, compared with non-treated T1DM stroke rats [11].
Further investigations are therefore warranted on the effects of BMSC treatment of stroke in
T2DM subjects.
Most preclinical studies focus on the measurement of BBB disruption and cerebral vascular
permeability during the early stage after stroke in diabetic animals, or employ histological
methods [6–8], which do not allow dynamic evaluation and application to patients. In the pres-
ent study, by employing magnetic resonance imaging (MRI), the temporal characteristics of
BBB disruption were monitored weekly up to 5 weeks after stroke in the T2DM rats with or
without BMSC treatments. Our primary and secondary endpoints are BBB leakage volume and
hemorrhagic volume, respectively, and we prospectively set the endpoints based on our prelim-
inary data. Thus, we can test our hypothesis that these MRI results will clarify, compared with
the controls, whether delayed treatment of stroke in T2DM rats with BMSC reduces BBB dam-
age and cerebral hemorrhage, as in non-diabetic rats, or fails to improve and even worsens
BBB damage, as in T1DM rats [11]. The present study also provides more detailed information
on longitudinal cerebrovascular damage after stroke and therapeutic efficacy of BMSC treat-
ment in T2DM rats.
Materials and Methods
All experimental procedures were conducted and performed in accordance with the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and under a pro-
tocol approved by the Institutional Animal Care and Use Committee of Henry Ford Health
System.
Animal model and experimental protocol
T2DM was induced in adult (175-200g, 2–3 months) male Wistar rats (Charles River, Wil-
mington, MA) by feeding them a high fat diet (HFD, 40% of calories as fat) for 2 weeks, then
intraperitoneally injecting a single low dose (35mg/kg) of streptozotocin (STZ, Zanosar1,
Sigma Chemical Co., St. Louis, MO), a naturally occurring chemical that is particularly toxic to
the insulin-producing beta cells of the pancreas in mammals, and the HFD was continued for
another two weeks. Distinguished from intraperitoneally injecting a single high dose (60mg/
kg) of STZ alone for type 1 diabetes, this fat-fed and STZ combination rat provides an animal
model for type 2 diabetes, and simulates the human clinic syndrome [12]. Although the HFD/
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STZ rat is widely employed as a model of T2DM [13–15], it is important to monitor the glucose
and insulin levels when using this model, since many factors may impact the T2DM pheno-
type, such as STZ dose, HFD duration, age and strain of rat [16]. Blood glucose level was mea-
sured using test strips for glucose (Polymer Technology System, Indianapolis, IN) for
confirmation of hyperglycemia. Rats with 8 hours fasting plasma glucose of300mg/dl were
considered diabetic and were selected for middle cerebral artery (MCA) occlusion [17].
Although the rat model of diabetes suggests insulin resistance, we cannot exclude the possibil-
ity that this model may be a mixed model of type 1 and type 2 diabetes, since we did not moni-
tor the insulin levels of diabetic rats in this study.[12]
The right MCA was occluded for 2 hours using the filament model [18]. Briefly, a 4–0
monofilament nylon suture, its tip rounded by heating, was introduced into the internal carotid
artery lumen through the stump of the external carotid artery and gently advanced into the
internal carotid artery 19-21mm past the common carotid artery bifurcation to block the origin
of the middle cerebral artery. Reperfusion was initiated by removal of the thread and tying off
the distal external carotid artery. During the surgery, rats were anesthetized with a gas flow
(1.0L/min) of isoflurane (1.5%) in a 2:1 mixture of N2O and O2. Buprenex (0.5mg/kg) was
intramuscularly injected once post surgery for pain relief. The animals were housed one rat per
cage with an enriched environment of small toys in each cage. Room temperature and humid-
ity were controlled at 70°F and 50%, respectively. Rats were observed once per day to make
sure that they were not in pain or discomfort, and they were able to function normally and had
free to access food and water.
Rats were randomly treated with either BMSC at a dose of 5 million (5x106) cells or an
equal volume of phosphate-buffered saline (PBS) as the vehicle via tail vein injection at 3 days
after MCA occlusion-reperfusion, the time of stroke and treatments were performed at a fixed
time of day. The dose selection is based on a previous study, in which treatment of stroke with
human umbilical cord blood cells at a dose of 5x106 initiated 3 days after stroke significantly
increased vascular and white matter remodeling in T2DM rats [17]. To avoid neuroprotective
effects, the treatment time point of 3 days after stroke in T2DM rats was used only to investi-
gate BMSC-induced neurorestorative effects, as well as to accommodate a wide treatment win-
dow. The treated (BMSC) and control (PBS) groups of T2DM rats with stroke were age and
body weight matched. Neurological function was monitored by modified neurological severity
scores (mNSS) [18] for all animals on days 1, 7, 14, 21, 28, and 35 post stroke.
MRI was performed prior to the MCA occlusion, as an internal control, and at one day and
then weekly for 5 weeks after ischemia-reperfusion for all rats. Among a total of 23 rats, seven
rats (3 from control and 4 from treated rats) died before completion of 5 weeks of MRI, and
were excluded from the study. No autopsy was performed on these rats. Animals did not
receive additional medical treatment, but were administered saline twice a day when the ani-
mals were dehydrated. After completing final MRI scans, all animals (n = 8 for BMSC and
n = 8 for PBS, respectively) were euthanized at 5 weeks post stroke.
MRI measurements
MRI measurements were performed with a 7T system (Bruker-Biospin, Ettlingen, Germany).
A birdcage type coil was used as the transmitter and a quardrature half-volume coil as the
receiver. Pulse sequences included T2-weighted imaging (T2WI), susceptibility weighted imag-
ing (SWI), contrast enhanced T1-weighted imaging (CE-T1WI) with gadopentetate, gadolin-
ium-diethylenetriamine penta-acetic acid (Magnevist1, Berlex Inc, Montville, NJ), as the
image contrast agent, and dynamic contrast-enhanced MRI (DCE-MRI) with the same single
administration of gadopentetate in CE-T1WI.
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A fast gradient echo imaging sequence was used for reproducible positioning of the animal
in the magnet at each MRI session. During MRI measurements, anesthesia was maintained
using medical air (1.0L/min) with isoflurane (1.0–1.5%). Stereotactic ear bars were used to
minimize movement, and rectal temperature was maintained at 37±1.0°C using a feedback
controlled water bath (YSI Inc, Yellow Springs, OH).
T2WI was acquired using a multislice (13 slices) and multiecho (6 echoes) sequence, with
time of echo (TE) as 15ms, and equally to 90ms, time of repetition (TR) as 4.5sec, a 32x32mm2
field-of-view (FOV), 1mm slice thickness and 128x64 matrix. SWI employed a specialized
3-dimensional gradient echo sequence with TE = 10ms, TR = 40ms, flip angle of 15°,
32x32x24mm3 FOV, 256x192x64 matrix, and flow compensation in all three directions.
CE-T1WI was composed of two T1-weighted imaging (T1WI) acquisitions, before and 6 min-
utes after injection of gadopentetate into a tail vein at a dose of 0.4mL/kg. T1WI was acquired
using a conventional multislice single spin-echo sequence with TE of 8ms, TR of 500ms and
the same other parameters as in T2WI.
The DCE-MRI was performed between the two T1WI acquisitions with a dual gradient
echo (DGE) sequence, and allowed to be run 15 seconds as a baseline followed by the gadopen-
tetate injection via tail vein. The TEs of the DGE sequence were 1.5ms and 8ms, respectively;
TR was 33ms; 3 continuous slices with 2mm thickness; 32x32mm2 FOV; 128x64 matrix. The
scan time was approximately 5 minutes by repeating the DGE sequence 150 times. The time-
dependent changes in R1 (1/T1) were used to form Ki map using the following equation:
CtisðtÞ ¼ Ki
Zt
0
CpaðtÞdtþ VpCpaðtÞ ð1Þ
where Ki is the blood-to-brain transfer constant, Ctis(t) is the tissue concentration of the con-
trast agent as a function of time, Cpa(t) is the plasma concentration of the contrast agent as a
function of time. Vp includes the entire volume of the rapidly filling sub-compartments. Esti-
mates of Ctis(t) and Cpa(t) are done via changes in the R1 values of cerebral tissue and sagittal
sinus blood. Pre-contrast T1 was estimated using a set of variable flip-angle spoiled gradient
recalled echo images aquired with TR 30ms, TE 4.0ms, flip-angles of 2°, 5°, 10°, 15°, 20° and
25° [19]; where the geometrical parameters were set to precisely match the DGE images after
image post-processing.
In this study, we focused on the volume of BBB disruption after stroke in diabetic rats.
Thus, CE-T1WI was employed to quantitatively measure the volume of BBB leakage, since the
CE-T1WI provides the similar and correlated results with the DCE-MRI,[20] as well as consis-
tent and comparable results with previous measurements in the stroke model of diabetic rat
without BMSC treatment.[21]
Histological staining
Rats were euthanized with ketamine (44mg/kg, intraperitoneal) and xylazine (13mg/kg, intra-
peritoneal) with the completion of MRI scans at 5 weeks after stroke. Brains were isolated,
post-fixed in 4% paraformaldehyde for 2 days at room temperature, and then processed for
paraffin sectioning. Coronal sections (6μm thick) were cut from each block and stained with
hematoxylin and eosin (H&E) for the evaluation of ischemic lesion and blood red cells in cere-
bral parenchymal tissue using light microscopy. A stain of fluorescein isothiocyanate dextran
(Sigma-Aldrich, St. Louis, MO) conjugated antibody against rat albumin was used for the spe-
cific and sensitive determination of BBB leakage.
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
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Data and statistical analysis
Experiment and data analysis were performed in a blind fashion. MRI image analysis was gen-
erally performed with homemade software, Eigentool [9]. T2 maps were obtained pixel-by-
pixel from multiple echoes of T2WI by using a linear least-squares fit to the plot of the natural
logarithm. SWI was produced using SPIN software [22], and then Eigentool was employed for
quantitative analysis after format transformation. Images of CE-T1WI were produced by sub-
tracting the images of pre gadopentetate T1WI from the images of post gadopentetate T1WI
with Eigentool. Each first echo image from the DGE sequence was employed to calculate the
changes of longitudinal relaxation time constant, T1, of the cerebral tissue voxel-by-voxel, and
hence to estimate concentration of gadopentetate infiltrated into brain tissue, leading to an esti-
mation of blood-to-brain permeability [23].
Ischemic lesion volumes of MRI were measured on the T2 maps. The mean plus two times
standard deviation of the contralateral measurements on the T2 maps was used as a threshold
to identify lesion volume. To eliminate the influence of brain atrophy after stroke, the ischemic
lesion volume were calculated and expressed as the ratio of lesion volume to contralateral
hemispheric volume. The same measurement was performed on the CE-T1WI images [20].
Due to hypointensity of hemorrhage on the SWI intensity image, the mean minus two times
standard deviation of the contralateral measurements was used as threshold to identify hemor-
rhage after stroke [24]. A hemorrhagic spot was counted if more than 3 pixels with 4-connected
neighborhoods were demarcated in each axial slice of SWI, and total number and volume of
hemorrhagic spots were summarized slice by slice. T1WI and SWI measurements were pre-
sented as the direct volumes.
The MicroComputer Imaging Device system (Imaging Research Inc, Ontario, Canada) was
used for histological measurements. H&E and albumin stained sections were evaluated at 40x
magnifications, respectively. The reactive areas inside striatum were measured (percentage to
FOV) under a 40x objective of the optical microscope, using an average of four locations as the
histological result.
MRI measurements are summarized as mean and standard deviation. Differences in the
MRI data between groups were analyzed by a mixed model of analysis of variance and covari-
ance, respectively. For the longitudinal MRI measurements, the analysis started testing the
group and time (without baseline time point) interaction, followed by testing the group differ-
ence at each time point (t-test) if the interaction or overall group effect was detected at the 0.05
level. Student`s t-test was performed for mNSS between the two groups of animals obtained at
5 weeks after stroke.
Results
The 8 hour fasting plasma glucose levels of selected rats measured prior to the induction of
middle cerebral artery occlusion was 377.4±50.4mg/dl for the saline treated rats and 385.1
±65.4mg/dl for the BMSC treated rats, respectively. Volumes of the ischemic lesion demarcated
from T2 maps did not exhibit any significant differences (p>0.1), as indicated in Fig 1A, within
5 weeks after stroke between the BMSC and PBS treated T2DM rats. After the onset of ische-
mia, lesion volumes experienced a sharp decline from 1d to 1w in all rats (Fig 1A), since brain
edema, which caused swelling of the ipsilateral brain hemisphere to approximately 16% greater
(p<0.0001) than the contralateral hemisphere at 1d after stroke, quickly faded in the first week.
For both control and BMSC treated T2DM rats, stroke lesion volumes demarcated from T2
maps exhibited similar temporal traces (Fig 1A), and were 33.8±15.3 percent (of the contralat-
eral hemisphere) versus 26.1±17.7 percent measured from T2 maps acquired at 5w after stroke,
or 39.3±12.9 percent versus 38.6±8.9 percent measured from the histological H&E coronal
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
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sections using the MicroComputer Imaging Device system, respectively. No significant differ-
ences in lesion volume were detected between the control and BMSC treated T2DM rats at 5w
after stroke (p>0.05).
BBB leakage of gadopentetate persisted for 5 weeks after stroke in the control T2DM rat
(upper row of CE-T1WI in Fig 2). Animals, having similar location and volume of stroke
lesion, were selected from control and treated groups, respectively, to avoid the effect of ische-
mic severity on BBB damage, and presented in Fig 2. However, for the BMSC treated T2DM
rat, hyperintensity, excluding the ventricle, in the ischemic brain tissue was present in the con-
trast enhanced images from 1 day to 3 weeks, rapidly faded at 4 weeks, and was hardly detect-
able at 5 weeks after stroke (lower row of CE-T1WI in Fig 2). The permeability rate maps,
derived from DCE-MRI and parameterized by the forward volume transfer constant Ki for the
estimated transfer rates of contrast agent (i.e., gadopentetate) across the microvasculature into
brain parenchyma, showed consistent results as the CE-T1WI for the two representative
T2DM rats with or without BMSC treatments (see Ki maps in Fig 2).
The quantitative volumes of gadopentetate enhancement with CE-T1WI demonstrated that
the BBB damage reached a peak at 1w after stroke in the control T2DM rats, as indicated in Fig
Fig 1. Quantitative measurements of MRI. Temporal traces of the ischemic lesion volumes demarcated from T2 maps (A) were close and no significant
differences (p>0.05) were detected after stroke, between the BMSC and saline treated T2DM rats. BBB disruption volumes of CE-T1WI with gadopentetate
enhancement (B) were significantly smaller in the BMSC treated T2DM rats than in the control rats from 1w after stroke. SWI measurements demonstrated
that BMSC treatment marginally reduced hemorrhagic volumes (C) at 5w, but significantly decreased hemorrhagic spots (D) starting 3w, after stroke in T2DM
rats.
doi:10.1371/journal.pone.0149147.g001
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
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1B. However, by mostly suppressing the increase of BBB damage at 1w after stroke (Fig 1B),
BMSC treatment significantly (p<0.05) reduced gadopentetate enhanced volumes from 1w to
5w after stroke in T2DM rats, compared with the control rats.
BBB disruption after ischemia may develop HT and lead to hemorrhage. In the SWI images,
the areas of hypointensity, excluding veins, are generally associated with hemorrhage [25]. Fig
Fig 2. Evolution of BBB disruption by MRI. BBB disruption, with enhancement in the subtracted images of pre and post gadopentetate of CE-T1WI,
persisted from 1w to 5w post stroke in saline treated, i.e., control, T2DM rat (C, the top row). In contrast, the hyperintensity regions faded from 4w after stroke
in BMSC treated T2DM rat (T, the second row). Permeability Ki maps demonstrated the similar results as CE-T1WI did for both control (C, the third row) and
the BMSC treated (T, the bottom row) rats.
doi:10.1371/journal.pone.0149147.g002
Fig 3. Evolution of hemorrhage by SWI. The evolution of hemorrhage after ischemia were demonstrated in SWI images for the representative control (C,
upper row) and BSMC treated (T, lower row) T2DM rats, respectively. Hemorrhagic volumes and spots were larger and more in the control T2DM rat than in
the BMSC treated T2DM rat in 5w after stroke.
doi:10.1371/journal.pone.0149147.g003
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3 shows the longitudinal SWI images from the two representative T2DM rats with and without
BMSC treatments. The SWI images exhibited much more severe hemorrhage in the control
T2DM rat than in the BMSC treated T2DM rat during 1d to 5w after stroke. Quantitative SWI
measurements for hemorrhagic volumes, as shown in Fig 1C, demonstrated that the BMSC
treated T2DM rats only exhibited marginally significant (p<0.08) smaller hemorrhagic vol-
umes than the control T2DM rats at 5w after stroke. However, hemorrhagic spots, demarcated
by SWI, were significantly (p<0.05) reduced from 3w to 5w after stroke in the BMSC treated
T2DM rats, in contrast to the control T2DM rats (Fig 1D).
Hemorrhage was histologically evaluated by counting erythrocytes outside of blood vessels
in the cerebral parenchymal tissue. Under the light microscope, H&E stained coronal sections
showed that red cells were diffusively present in the ischemic cerebral tissue in the control
T2DM rat, as indicated in Fig 4A; while fewer red blood cells were present and were localized
to a smaller region in the BMSC treated T2DM rat than in the control T2DM rat (Fig 4B). Mea-
surements of red blood cells with H&E stain were 13.3±4.2 percent versus 7.1±3.8 percent for
the control and BMSC treated rats, respectively, and no significant differences were found.
Albumin stain provides a means to assess BBB leakage for large molecules. The albumin immu-
noreactive spots outside of blood vessels in the brain parenchymal tissue were larger and more
dense for the control T2DM rat (Fig 4C) than that for the BMSC treated rat (Fig 4D). Measure-
ments of percent albumin stain areas were 5.4±3.0 percent versus 2.0±0.9 percent for the con-
trol and BMSC treated rats, respectively, with a significant difference (p<0.05). Thus,
coinciding with the MRI measurements, histological results of H&E and albumin stainings for
BBB damage demonstrated that BMSC treatment of stroke in T2DM rats significantly reduced
Fig 4. Histology of BBB disruption and hemorrhage.With the histological H&E stained sections under the
light microscope, hemorrhage was found with more red cells and more diffusively distributed in the ischemic
cerebral tissue in the control T2DM rat (A, 40x), than in the BMSC treated T2DM rat (B, 40x). Albumin stain
demonstrated that the BBB leakage was more severe in the control T2DM rat (C, 20x) than in the BMSC
treated T2DM rat (D, 20x). Bars: 50μm in B & 100μm in D.
doi:10.1371/journal.pone.0149147.g004
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cerebral vascular leakage after stroke and substantially reduced hemorrhage compared to the
control T2DM rats.
Neurological function graded by mNSS was performed. The BMSC treatment of stroke in
T2DM rats significantly (p<0.05) improved neurological function of rats at 5 weeks after
stroke with the mNSS of 6.33±1.50 for the saline treated T2DM rats and 5.11±0.60 for the
BMSC treated rats, respectively.
Discussion
BMSC treatment of stroke in previous experimental studies demonstrated differential thera-
peutic effects on vascular permeability in non-diabetic rats, where the treatment significantly
reduced BBB leakage [26], and in T1DM rats, where the treatment increased BBB leakage [11].
Thus, there is a need to clarify the therapeutic effects of BMSC on vascular permeability in
T2DM stroke rats. By employing CE-T1WI with gadopentetate, the present study demon-
strates that, compared with the saline treatment, BMSC therapy administered at 3 days after
stroke significantly (p<0.05) decreases BBB leakage in T2DM rats starting at 1 week after
stroke, hence, leading to a significant (p<0.05) reduction of hemorrhagic spots starting from
3w after stroke and a marginally significant (p<0.08) reduction of hemorrhagic volume at 5w
after stroke demarcated from SWI. The differences in vascular response of T1DM and T2DM
stroke rats to BMSC treatment may be dependent on the time at which treatment is initiated,
where cell administration were at 1 day and 3 days after stroke in T1DM and T2DM, respec-
tively, and not necessarily on pathophysiological differences between T1DM and T2DM [11].
Delayed BMSC treatment of stroke in rats is not neuroprotective, and does not reduce
infarction volume. It is neurorestorative. Neurorestorative approaches, essentially treat the
intact tissue to promote neurovascular remodeling which enhances neurological recovery.
Examples of neurovascular remodeling include angiogenesis [27], neurogenesis [18], oligoden-
drogenesis [28], synaptogenesis and axonal sprouting throughout the central nervous system
[29, 30].
By employing dynamic T2WI measurements, we found that treatment of stroke with BMSC
in T2DM rats does not reduce infarction volume during 5 weeks after stroke, compared to
saline treated T2DM rats. Thus, administration of BMSCs initiated at 3 days after stroke in
T2DM rats is not neuroprotective. However, the reduction of BBB leakage may be a biomarker
of BMSC-induced neurorestorative effects. These data are consistent with prior reports that
cell treatment administered at or more than 24 hours post stroke to non-diabetic rats or to
T1DM rats does not reduce ischemic lesion volumes [11, 31]. Immunohistochemical measure-
ments of infarction, BBB leakage and hemorrhage at 5w after stroke present consistent results
with MRI measurements.
Hyperglycemia induces biochemical changes within endothelial cells [2], leading to vascular
endothelial cell dysfunction, and increased vascular permeability [3]. As a result, more severe
vascular damage has been consistently documented in stroke patients and animals with diabe-
tes [3, 4]. In the present MRI study, gadopentetate, molecular weight of approximate 1KDa,
was employed as a hallmark of BBB disruption. The intact BBB can hinder crossing of gado-
pentetate. However, because of breakdown of basal lamina with loss of astrocyte and endothe-
lial cell contact, disruption of the BBB after ischemia allows accumulation of gadopentetate out
of vessels in brain parenchyma, which primarily increases image intensity of cerebral tissue
where it accumulates, leading to T1WI enhancement [20]. The enhancement may be inter-
preted as BBB damage leading to leakage of gadopentetate out of vessels into brain tissue, and
not as increased vascular volume, since temporal functions of contrast concentration in cere-
bral vessels and tissue differ in response to the tail vein injection of the contrast, where the
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
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gadopentetate concentration in cerebral vessels rapidly rises and falls, while the gadopentetate
concentration in cerebral tissue decreases very slowly after rising to its peak. Thus, BMSC treat-
ment reduces gadopentetate enhanced volume after stroke in T2DM rats, compared with con-
trol rats, which implies that BMSC treatment decreased BBB disruption.
CE-T1WI with the administration of Gd-DTPA demonstrated different temporal features
of blood vascular permeability between the control and BMSC treated T2DM rats, as indicated
in Fig 2 from two representative animals. The contrast enhanced images, by subtraction of pre-
contrast from post-contrast images of CE-T1WI, exhibited regions with elevated intensity in
ischemic cerebral tissue, which indicated BBB damage leading to leakage of Gd-DTPA out of
vessels into brain tissue.
With the same administration of gadopentetate, the differences between CE-T1WI and
DCE-MRI are as follows: CE-T1WI is a convenient and quick method to detect BBB leakage in
brain by comparing pre and post gadopentetate images, while the DCE-MRI method provides
quantitative BBB permeability rate, Ki, by modeling analysis of dynamic images with gadopen-
tetate enhancement [23]. Measurements from CE-T1WI images and Ki maps are correlated in
the ischemic brain of rats after stroke [20]. In the present study, as indicated in Fig 2, Ki maps
and subtracted CE-T1WI images exhibit similar temporal patterns of BBB disruption in T2DM
rats after stroke with or without the BMSC treatments. According to Eq 1, the Patlak plot is a
straight line, and there is no information to estimate the interstitial volume. The ratio of per-
meability-surface product over flow is far less than 1, and the flow effect on Ki can be neglected.
Permeability (Ki) and vascular volume (Vp) are separated in Eq 1. Hence, the Ki may be inter-
preted as specific for endothelial permeability [32].
The evaluation of BBB disruption employing CE-T1WI depends on the size of contrast
agent used in the experiment [20]. BBB damage increases permeability to small molecules at an
early stage after stroke, such as gadopentetate. At later times, proteins or cells, e.g. albumin or
erythrocytes, may penetrate the disrupted BBB. Erythrocytes die after leaving a ruptured blood
vessel, and release the hemoglobin into the extracellular space. Extracellular hemoglobin loses
oxygen and becomes paramagnetic deoxyhemoglobin, or can be engulfed by phagocytic cells
and degraded into hemosiderin. SWI can detect changes of magnetic susceptibility induced by
deoxyhemoglobin or hemosiderin. Thus, the CE-T1WI evaluation for BBB leakage need not be
correlated with the SWI measurements for hemorrhage. As indicated in Fig 5, three pairs of
images typically demonstrated different situations of BBB leakage and hemorrhage by
Fig 5. Mismatch of BBB disruption and hemorrhage. The locations of BBB disruption with high
permeability Ki values of gadopentetate and the spots of hemorrhage with hypointensity of SWI, were found
overlapped (A1 & A2), dislocated (B1 & B2), i.e., did not overlap, and inconsistent (C1 & C2), i.e., elevated
permeability without detectable hemorrhage.
doi:10.1371/journal.pone.0149147.g005
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CE-T1WI and SWI, respectively. Therefore, unlike the significant differences in volumes of
BBB leakage detected by CE-T1WI, hemorrhagic volumes, detected by SWI, only exhibit mar-
ginally significant differences between the BMSC and saline treated T2DM rats after stroke.
HT after ischemia mostly occurs during the first week after stroke, and blood can persist in
brain tissue and be continuously detected by SWI in six weeks after stroke in non-diabetic rats
[24]. In contrast, stroke causes chronic and widespread BBB damage in T2DM rats [9]. Fur-
thermore, according to our results, HT after stroke in T2DM rats, differs from that in the non-
diabetic rats, results in multiple hemorrhagic spots in SWI (Fig 3), mostly, during the first
week after stroke (Figs 1D and 3). Thus, treatment with BMSC at 3 days after onset of stroke in
the present study essentially misses the first half week of hemorrhagic time window, and can
only partly reduce HT by subsequently ameliorating damage of BBB. From this point of view,
although hemorrhagic volume did not exhibit a significant difference between the BMSC and
saline treated T2DM rats in 5w after stroke, BMSC treatment of stroke effectively protected
BBB from further damage in T2DM rats, leading to a significant reduction of HT spots starting
from 3 weeks after stroke (Fig 1D). However, in addition to decreasing hemorrhagic spots,
BMSC treatment increases vascular endothelial growth factor expression and angiogenesis
[27], which may lead to the marginally significant (p<0.08) reduction of hemorrhagic volume
in treated T2DM rats at 5w after stroke, compared with the controls (Fig 1C).
In the present study, CE-T1WI detects BBB leakage of gadopentetate, and modulus images
are reconstructed from SWI and employed to detect deoxyhemoglobin or hemosiderin as hem-
orrhagic evidence in the ischemic brain of T2DM rats. MRI markers differ from histological
stains for either BBB leakage of albumin or hemorrhagic evidence of erythrocytes. Thus, the
histological albumin and H&E measurements provide evidence to support MRI results, which
demonstrated that BMSC treatment significantly reduced BBB disruption and leads to reduced
hemorrhage after stroke in T2DM rats, compared with the vehicle treated T2DM rats.
In summary, the hypothesis of this study was successfully tested that the delayed, i.e. 3 days
after stroke, treatment of T2DM rats with BMSC promotes neurorestorative effects, reduces
BBB disruption, and improves functional outcome. These gadopentetate related MRI findings
are consistent with, and supported by histological results of albumin and H&E stainings for
BBB disruption.
Acknowledgments
This work was financially supported by NIH RO1 NS083078 (JC), NS064134 (QJ), AG037506
(MC), R41 S080329 (JC), and American Heart Association (AHA) 14GRNT20460026 (JC).
The content is solely the responsibility of the authors and does not necessarily represent the
official view of the National Institutes of Health.
Author Contributions
Conceived and designed the experiments: JC MC QJ. Performed the experiments: GD TY CC.
Analyzed the data: LL GD QL SD TY CC. Contributed reagents/materials/analysis tools: LL SD
TY CC. Wrote the paper: GDMC QJ JC. Study Supervision: MC.
References
1. Ergul A, Li W, Elgebaly MM, Bruno A, Fagan SC. Hyperglycemia, diabetes and stroke: focus on the cer-
ebrovasculature. Vascular pharmacology. 2009; 51(1):44–9. Epub 2009/03/05. doi: 10.1016/j.vph.
2009.02.004 PMID: 19258053; PubMed Central PMCID: PMCPMC3732462.
2. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414
(6865):813–20. Epub 2001/12/14. doi: 10.1038/414813a PMID: 11742414.
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
PLOS ONE | DOI:10.1371/journal.pone.0149147 February 22, 2016 11 / 13
3. Li W, Qu Z, Prakash R, Chung C, Ma H, Hoda MN, et al. Comparative analysis of the neurovascular
injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats. Brain Res.
2013; 1541:106–14. Epub 2013/10/23. doi: 10.1016/j.brainres.2013.10.021 PMID: 24144674; PubMed
Central PMCID: PMCPMC3878856.
4. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood
Flow Metab. 2007; 27(3):435–51. Epub 2006/06/29. doi: 10.1038/sj.jcbfm.9600355 PMID: 16804552.
5. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. International journal of clinical practice.
2006; 60(1):48–56. Epub 2006/01/18. doi: 10.1111/j.1368-5031.2006.00682.x PMID: 16409428.
6. Chen J, Cui X, Zacharek A, Cui Y, Roberts C, Chopp M. White matter damage and the effect of matrix
metalloproteinases in type 2 diabetic mice after stroke. Stroke. 2011; 42(2):445–52. doi: 10.1161/
STROKEAHA.110.596486 PMID: 21193743; PubMed Central PMCID: PMC3108495.
7. Wei N, Yu SP, Gu XH, Chen DD, Whalin MK, Xu GL, et al. The involvement of autophagy pathway in
exaggerated ischemic brain damage in diabetic mice. CNS neuroscience & therapeutics. 2013; 19
(10):753–63. Epub 2013/06/05. doi: 10.1111/cns.12123 PMID: 23731488.
8. Ergul A, Elgebaly MM, Middlemore ML, Li W, Elewa H, Switzer JA, et al. Increased hemorrhagic trans-
formation and altered infarct size and localization after experimental stroke in a rat model type 2 diabe-
tes. BMC neurology. 2007; 7:33. Epub 2007/10/17. doi: 10.1186/1471-2377-7-33 PMID: 17937795;
PubMed Central PMCID: PMCPMC2098774.
9. Ding G, Yan T, Chen J, Chopp M, Li L, Li Q, et al. Persistent cerebrovascular damage after stroke in
type two diabetic rats measured by magnetic resonance imaging. Stroke. 2015; 46(2):507–12. Epub
2014/12/20. doi: 10.1161/STROKEAHA.114.007538 PMID: 25523056; PubMed Central PMCID:
PMC4308544.
10. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol. 2002; 1(2):92–100.
PMID: 12849513.
11. Chen J, Ye X, Yan T, Zhang C, Yang XP, Cui X, et al. Adverse effects of bone marrow stromal cell treat-
ment of stroke in diabetic rats. Stroke. 2011; 42(12):3551–8. Epub 2011/09/24. doi: 10.1161/strokeaha.
111.627174 PMID: 21940967; PubMed Central PMCID: PMCPMC3264886.
12. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, et al. A new rat model of type
2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism. 2000; 49(11):1390–4. doi: 10.1053/
meta.2000.17721 PMID: 11092499.
13. Piotrowski P. Are experimental models useful for analysis of pathogenesis of changes in central ner-
vous system in human diabetes? Folia neuropathologica / Association of Polish Neuropathologists and
Medical Research Centre, Polish Academy of Sciences. 2003; 41(3):167–74. Epub 2003/11/08. PMID:
14604299.
14. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: diabetic neuropathy and effects of
rosuvastatin on neurovascular function in diabetes models. Diabetes research and clinical practice.
2003; 61 Suppl 1:S35–9. Epub 2003/07/26. PMID: 12880693.
15. Yu DY, Cringle SJ, Su EN, Yu PK, Jerums G, Cooper ME. Pathogenesis and intervention strategies in
diabetic retinopathy. Clinical & experimental ophthalmology. 2001; 29(3):164–6. Epub 2001/07/12.
PMID: 11446460.
16. Skovsø S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. Journal of Diabetes
Investigation. 2014; 5(4):349–58. doi: 10.1111/jdi.12235 PMID: 25411593
17. Yan T, Venkat P, Chopp M, Zacharek A, Ning R, Cui Y, et al. Neurorestorative Therapy of Stroke in
Type 2 Diabetes Mellitus Rats TreatedWith Human Umbilical Cord Blood Cells. Stroke. 2015; 46
(9):2599–606. Epub 2015/08/06. doi: 10.1161/strokeaha.115.009870 PMID: 26243222; PubMed Cen-
tral PMCID: PMCPMC4550506.
18. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of
bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001; 32(4):1005–11. PMID:
11283404.
19. Liberman G, Louzoun Y, Ben Bashat D. T1 Mapping using variable flip angle SPGR data with flip angle
correction.
20. Ding G, Zhang Z, Chopp M, Li L, Zhang L, Li Q, et al. MRI evaluation of BBB disruption after adjuvant
AcSDKP treatment of stroke with tPA in rat. Neuroscience. 2014; 271:1–8. Epub 2014/04/29. doi: 10.
1016/j.neuroscience.2014.04.025 PMID: 24769225; PubMed Central PMCID: PMC4044825.
21. Ding G, Chen J, Chopp M, Li L, Yan T, Davoodi-Bojd E, et al. White matter changes after stroke in type
2 diabetic rats measured by diffusion magnetic resonance imaging. J Cereb Blood Flow Metab. 2015.
Epub 2015/12/20. doi: 10.1177/0271678x15622464 PMID: 26685128.
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
PLOS ONE | DOI:10.1371/journal.pone.0149147 February 22, 2016 12 / 13
22. Tong KA, Ashwal S, Holshouser BA, Shutter LA, Herigault G, Haacke EM, et al. Hemorrhagic shearing
lesions in children and adolescents with posttraumatic diffuse axonal injury: improved detection and ini-
tial results. Radiology. 2003; 227(2):332–9. doi: 10.1148/radiol.2272020176 PMID: 12732694.
23. Aryal MP, Nagaraja TN, Brown SL, Lu M, Bagher-Ebadian H, Ding G, et al. Intratumor distribution and
test-retest comparisons of physiological parameters quantified by dynamic contrast-enhanced MRI in
rat U251 glioma. NMR Biomed. 2014; 27(10):1230–8. Epub 2014/08/16. doi: 10.1002/nbm.3178 PMID:
25125367; PubMed Central PMCID: PMC4160378.
24. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, et al. Angiogenesis detected after embolic
stroke in rat brain using magnetic resonance T2*WI. Stroke. 2008; 39(5):1563–8. doi: 10.1161/
STROKEAHA.107.502146 PMID: 18356548; PubMed Central PMCID: PMC2581408.
25. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility-weighted imaging: technical aspects
and clinical applications, part 1. AJNR Am J Neuroradiol. 2009; 30(1):19–30. doi: 10.3174/ajnr.A1400
PMID: 19039041; PubMed Central PMCID: PMC3805391.
26. Zacharek A, Chen J, Cui X, Li A, Li Y, Roberts C, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by
MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow
Metab. 2007; 27(10):1684–91. doi: 10.1038/sj.jcbfm.9600475 PMID: 17356562; PubMed Central
PMCID: PMC2796470.
27. Chen J, Zhang ZG, Li Y, Wang L, Xu YX, Gautam SC, et al. Intravenous administration of human bone
marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ
Res. 2003; 92(6):692–9. doi: 10.1161/01.RES.0000063425.51108.8D PMID: 12609969.
28. Li Y, Chen J, Zhang CL, Wang L, Lu D, Katakowski M, et al. Gliosis and brain remodeling after treat-
ment of stroke in rats with marrow stromal cells. Glia. 2005; 49(3):407–17. doi: 10.1002/glia.20126
PMID: 15540231.
29. Li Y, Chopp M. Marrow stromal cell transplantation in stroke and traumatic brain injury. Neurosci Lett.
2009; 456(3):120–3. doi: 10.1016/j.neulet.2008.03.096 PMID: 19429146; PubMed Central PMCID:
PMC3359793.
30. Shen LH, Li Y, Chen J, Zhang J, Vanguri P, Borneman J, et al. Intracarotid transplantation of bone mar-
row stromal cells increases axon-myelin remodeling after stroke. Neuroscience. 2006; 137(2):393–9.
doi: 10.1016/j.neuroscience.2005.08.092 PMID: 16298076.
31. Zhang C, Li Y, Chen J, Gao Q, Zacharek A, Kapke A, et al. Bone marrow stromal cells upregulate
expression of bone morphogenetic proteins 2 and 4, gap junction protein connexin-43 and synaptophy-
sin after stroke in rats. Neuroscience. 2006; 141(2):687–95. Epub 2006/05/30. doi: 10.1016/j.
neuroscience.2006.04.054 PMID: 16730912.
32. Ewing JR, Bagher-Ebadian H. Model selection in measures of vascular parameters using dynamic con-
trast-enhanced MRI: experimental and clinical applications. NMR Biomed. 2013; 26(8):1028–41. Epub
2013/07/25. doi: 10.1002/nbm.2996 PMID: 23881857; PubMed Central PMCID: PMCPMC3752406.
Cell Therapy Reduces BBB Damage in T2DM Stroke Rats
PLOS ONE | DOI:10.1371/journal.pone.0149147 February 22, 2016 13 / 13
